[101] Study 329: Why is it so important?

Study 329: Why is it so important?

[101] Study 329: Why is it so important?

Study 329Study 329 is a GlaxoSmithKline (GSK) sponsored trial with 22 academic authors that compared paroxetine, imipramine, and placebo for adolescent depression. In this trial 275 adolescents with major depression were randomized in a double-blind fashion to paroxetine (93), imipramine (95) or placebo (87) for 8 weeks. Those who completed 8 weeks were studied in a 6-month continuation phase.

Published 8-week results (2001)1: Compared with placebo, paroxetine demonstrated significantly greater improvement in 3 selected depression rating scales and a Clinical Global Improvement score of 1 or 2. The response to imipramine was not significantly different from placebo for any measure.

Authors’ conclusions: “Paroxetine is generally well tolerated and effective for major depression in adolescents.”1

This trial has been cited over 600 times and was very influential in increasing prescribing of paroxetine in this clinical setting.2

Did these published conclusions reflect “reality”?

Critical appraisal of the 2001 publication would have led to questions about the authors’ conclusions. The differences between paroxetine and placebo were small, and the authors noted that neither paroxetine nor imipramine differed significantly from placebo for parent- or self-rating measures of depression. Furthermore, serious adverse events occurred in 11 patients in the paroxetine group, 5 in the imipramine group, and 2 in the placebo group. Ten of the 11 serious adverse events in the paroxetine group were psychiatric, e.g. depression, suicidality, hostility or euphoria.1 In 2004, Garland called attention to the “weak or nonexistent evidence of efficacy” of SSRIs in this setting and the “serious psychiatric adverse effects” of paroxetine.3

A solution: Restoring Invisible and Abandoned Trials (RIAT) initiative

The RIAT initiative is an attempt by independent researchers to analyze and publish misreported or unpublished trials.4 The RIAT researchers identified Study 329 as an example of a potentially misreported acute phase trial in need of restoration and an unpublished continuation phase trial that had been abandoned. The restored trial5 and the abandoned trial6 are now published.

The publications report in detail the methods used to re-analyze Study 329. Notably, they followed the protocol (and amendments) established by GSK7 and used all appropriate procedural steps to avoid bias. They have also made the original anonymous patient data available for others to analyze.

RIAT analysis of Study 329 (acute phase)

The trial protocol7 specified two primary efficacy variables: change in total score on a Hamilton depression rating scale (HAM-D) from baseline to endpoint, and the proportion of responders at the end of 8 weeks. Responders were defined as achieving a reduction of ≥50% in HAM-D score, or a score of ≤8. It also specified seven secondary efficacy variables.

Results: Paroxetine and imipramine were not statistically or clinically significantly different from placebo for any of the 9 pre-specified primary or secondary efficacy outcomes. The four statistically significant outcomes in the 2001 publication1 were neither specified in the original protocol nor in any amendment. Withdrawals due to adverse effects occurred in 15% of subjects taking paroxetine, 32.6% taking imipramine and 6.9% taking placebo. This was predominantly due to 12% of subjects experiencing adverse psychiatric effects with paroxetine and 16% of subjects experiencing adverse cardiovascular effects with imipramine. More paroxetine adverse events were rated as severe.

RIAT authors’ conclusions: “Neither paroxetine nor high dose imipramine were efficacious for major depression in adolescents, whereas both drugs increased harms.”5

This example demonstrates and emphasizes the importance of independent access to data, and the value of reanalysis of trials. The implications for clinical practice are enormous and apply beyond this setting to the use of antidepressants in adult depression and to other drugs and indications.8 

RIAT analysis of Study 329 (continuation phase)

The continuation phase of Study 329 was designed to assess relapse rates in the longer term and to assess safety while patients were on drug or placebo and during a tapering discontinuation phase.6 Tapering was recommended for all patients, whether they left either phase of the study early, completed the acute phase but did not continue, or completed the six-month continuation phase. If the patient accepted a taper phase, the protocol recommended tapering medication or placebo over 7-17 days. Of 190 adolescents who completed the eight-week acute phase, 119 entered the 6-month continuation phase (paroxetine n = 49; imipramine n = 39; placebo n = 31).

Results: In these 119 subjects the response rate at 6 months was the same for all 3 treatments: 31% on paroxetine, 31% on imipramine and 39% on placebo. In the continuation phase, adverse event rates were similar for the 3 groups. During tapering, severe adverse events were much higher for the drugs: paroxetine 16, imipramine 14 and placebo 1. Suicidality and suicide-related events were of particular concern during acute treatment, 6 month continuation, and taper: paroxetine 23 events in 15 patients, imipramine 11 events in 9 patients and placebo 5 events in 5 patients. With paroxetine, 5 of the suicide-related events occurred in 5 patients during the taper phase.

Conclusions: The continuation phase did not offer support for longer-term efficacy of either paroxetine or imipramine but demonstrated additional safety concerns for both drugs in the taper phase and particularly adverse psychiatric events with paroxetine.6

What has happened as a result of these revelations?

Nothing. A British Medical Journal editorial2 documents that there has been no correction, no retraction, no apology and mostly no comment from the authors, journal editor, or from the universities where authors worked in 2001.

The RIAT analyses of Study 329 and the lack of any correction of the original flawed paper have major implications for clinical practice decisions being made on the basis of published clinical trials. Leading experts on clinical trials now believe that we must question the validity of the data and conclusions of all published clinical trials that have not been subject to independent analysis.9


  • Independent analysis of Study 329 demonstrated serious harms and a lack of efficacy for acute and longer-term use of paroxetine and imipramine for adolescents with major depression.
  • This example of the RIAT initiative reveals that the current methods of trial conduct, analysis and publication are unacceptable.
  • Published conclusions about efficacy and safety of drugs without independent analysis cannot be accepted as trustworthy.
  • It is essential that primary trial data and protocols for all clinical trials be made available for independent analysis.

The draft of this Therapeutics Letter was submitted for review to 70 experts and primary care physicians in order to correct any inaccuracies and to ensure that the information is concise and relevant to clinicians.
The Therapeutics Initiative is funded by the BC Ministry of Health through a grant to the University of BC. The Therapeutics Initiative provides evidence-based advice about drug therapy, and is not responsible for formulating or adjudicating provincial drug policies .
ISSN 2369-8691 (Online) <||> ISSN 2369-8683 (Print)


  1. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40(7):762-72. DOI:10.1097/00004583-200107000-00010
  2. Doshi P. No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. BMJ. 2015; 351:h4629. DOI:10.1136/bmj.h4629
  3. Garland EJ. Facing the evidence: antidepressant treatment in children and adolescents. CMAJ. 2004; 170(4):489-91. PMCID:PMC332716
  4. Doshi P, Dickersin K, Healy D, et al. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ. 2013; 346:f2865. DOI:10.1136/bmj.f2865
  5. Le Noury JC, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015; 351:h4320. DOI:10.1136/bmj.h4320
  6. Le Noury JC, Nardo JM, Healy D, et al. Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. International Journal of Risk & Safety in Medicine. 2016; 28(3):143–61. DOI: DOI:10.3233/JRS-160728
  7. SmithKline Beecham. A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression. Protocol number 29060/329. 1993, amended 1994, 1996. [Internet]. Available from: www.gsk.com/media/360485/329-AppA.PDF [Accessed 29 February 2016].
  8. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ 2016; November 14. DOI: 10.1503/cmaj.151104
  9. Ioannidis JP. Why most clinical research is not useful. PLoS Med. 2016; 13(6):e1002049. DOI:10.1371/journal.pmed.1002049
  • Larry D. Sasich
    Posted at 09:04h, 23 November Reply

    Paroxetine and Study 329 – What We Already Knew and When

    The Therapeutics Initiative and the published re-analysis of Study 329 [1] failed to mention that it has been known since at least 1998 from the publically available US FDA’s Drug Approval Package that paroxetine had not been shown to be safe and effective in younger populations.[2] This information was available to the public three years before the original publication of Study 329 in 2001. Since the mid-2000s the FDA professional product information for paroxetine is required to display a Box Warning that paroxetine is not approved for use in pediatric patients. A Box Warning is the strongest type of warning that the FDA can require in a drug’s professional product information.

    Any positive impact on patient safety from the re-analysis of the Study 329 trial 14 years after the original study was published is questionable. A lesson that should be learned from Study 329 is that patient drug safety may be better served by promoting and placing the information from FDA regulatory summary documents, professional product labels, and Medication Guides in the hands of patients and their parents.


    1. Le Noury JC, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015; 351:h4320. DOI:10.1136/bmj.h4320.

    2. Dubitsky GM. Food and Drug Administration Review and Evaluation of Paroxetine Controlled Released Tablets, July 17, 1998. http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-936_Paxil_medr_P1.pdf. Accessed February 2, 2016.

    3. Apotex Corp. Professional Product Label: Paxil CR (Paroxetine), July 12, 2015. At http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=483bd97f-c4d0-4e23-aaa8-6334f4471e0c. Accessed November 23, 2016.

    • Aaron Tejani
      Posted at 08:01h, 05 December Reply

      We very much appreciate the comment by Larry Sasich and agree with his points and suggestions. The sad reality is that despite the fact that this FDA information has been available and the reanalysis of Study 329 has been published for over a year, there has been little or no impact on prescribing or on the people who authored the flawed publication in 2001. As a result we strongly believe that this issue requires continued promotion by us and others.

Post A Comment